For better or for worse, that's not the case for the bottom-performers list, which features a much more wide-ranging group of funds. From health care to commodities to China, there's a host of different types of ETFs that are faring poorly this year.
That's unsurprising considering that the broad market is still down for the year even after stocks rallied strongly in the second half of February and the first session of March. As of the close on March 1, the SPDR S&P 500 (SPY | A-98) was down 2.9% year-to-date.
That compares to losses for the 15 ETFs at the bottom of the heap so far in 2016 that range from 23.1% to as much as 46.1%.
Two Troubled ETNs
Taking the Nos. 1 and 2 positions on this worst-performers list are two exchange-traded notes with little in the way of assets.
The iPath Global Carbon ETN (GRN | F) dropped more than 46% just in the first two months of the year, following the carbon credit market lower.
Meanwhile, the thinly traded iPath Bloomberg Natural Gas Subindex Total Return ETN (GAZ | F-65) lost 43.2% through March 1. Effectively a broken product, GAZ has been closed to new creations for some time now, which has led to big distortions in the price of the ETN.
Issuer Barclays has warned that GAZ may cease to trade or may decline to zero if natural gas prices continue to tumble.
The ETFs that appeared the most on the worst-performers list are those related to health care―specifically, biotech. A total of six health care funds were in the bottom 15 as the sector tanked to start the year.
Scandal grips some of the top names in the industry, while the specter of political uncertainty and potential regulations also hangs over the biotech space.
The BioShares Biotechnology Clinical Trials ETF (BBC), the ALPS Medical Breakthroughs ETF (SBIO), and the PowerShares Dynamic Biotech & Genome ETF (PBE | B-49) are a few of this year's dismal biotech performers. Losses for these ETFs range from 23.1% to 38.6%.
NatGas & China Struggle
Last year, energy ETFs dominated the bottom-performers list. So far this year, they're still doing poorly, but to a lesser degree.
In addition to GAZ, another natural gas product―the First Trust ISE-Revere Natural Gas ETF (FCG | B-95)―made the cut with a loss of 23.5%.
So too did the PowerShares Dynamic Energy Exploration & Production ETF (PXE | B-65), a product that in addition to holding E&P companies, is heavily on oil refiners. PXE shed 22.6% this year.
Finally, one familiar area that's struggled and dominated the headlines for months is China. Thus, it's not a shock to see two ETFs related to that country perform particularly poorly.
The Market Vectors ChinaAMC SME-ChiNext ETF (CNXT | D-54)―last year's top-performing ETF―is down 28.6% so far this year, while the Deutsche X-trackers Harvest CSI 500 China A-Shares ETF (ASHS | F-57) is down 26.8%.
15 Worst-Performing ETFs Of 2016 To-Date
|Ticker||Fund||TD Return (%)|
|GRN||iPath Global Carbon ETN||-46.13|
|GAZ||iPath Bloomberg Natural Gas Subindex Total Return ETN||-43.24|
|BBC||BioShares Biotechnology Clinical Trials||-37.63|
|SBIO||ALPS Medical Breakthroughs||-31.23|
|DPU||DB Commodity Long ETN||-29.51|
|CNXT||Market Vectors ChinaAMC SME-ChiNext||-28.61|
|ASHS||Deutsche X-trackers Harvest CSI 500 China-A Shares Small Cap||-26.8|
|CNCR||Loncar Cancer Immunotherapy||-25.96|
|DXJF||WisdomTree Japan Hedged Financials||-25.03|
|PBE||PowerShares Dynamic Biotech & Genome||-24.46|
|PTH||PowerShares DWA Healthcare Momentum||-23.99|
|FCG||First Trust ISE-Revere Natural Gas||-23.54|
|BBP||BioShares Biotechnology Products||-23.1|
|PXE||PowerShares Dynamic Energy Exploration & Production||-22.64|
Data through March 1, 2016
Contact Sumit Roy at [email protected].